Using the EU-OPENSCREEN bioactives library: Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen:

Compound repurposing is an important strategy for the identification of effective treatment options against SARS-CoV-2 infection and COVID-19 disease. The EU-OPENSCREEN high capacity screening partner site, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Hamburg, Germany, applied high-content screening to a large drug repurposing collection investigating compound’s ability to inhibit SARS-CoV-2 cytopathicity in the human epithelial colorectal adenocarcinoma cell line, Caco-2. By targeting the SARS-CoV-2 main protease 3CL-Pro that plays a central role in viral replication, the study confirmed previously reported inhibitors and identified 62 additional compounds with promising anti-viral activity. 

► Read here the highlight by EU-OPENSCREEN. ( 

We use cookies to analyse the traffic on our websites. All personal data is anonymized and not shared with third parties! more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.